Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed P…
| Métrica | SVNS.L | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -92.7% | -39.2% | -53.5% |
| ROA | -75.7% | -30.9% | -44.7% |
| Current Ratio | 4.00 | 2.73 | +1.27 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -75.7% | — |
| ✗Flujo de caja operativo positivo | −£3M | −£1M |
| ✗Rentabilidad sobre activos al alza | -75.7% | -49.6% |
| ✓Caja operativa/activos supera al ROA | -43.2% | ROA -75.7% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 4.00 | 6.85 |
| ✗Sin aumentar el nº de acciones | — | — |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.00 | 0.00 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -80.8% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
SOLVONIS THERAPEUTICS PLC cotiza a 0.00 GBP y tiene una capitalización bursátil de £8M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud